Aclarion

ACON · NASDAQ

$1.97+$0.08 (+4.23%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $1.89

ACON analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $7.65 (+288.3% upside)

Low: $7.57
Now: $1.97
High: $7.88

Upgrades and downgrades

The latest rating actions, newest first

ACON analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	May 29, 2026	Maintains	Buy	$7.00 → $7.50	19%
Ascendiant Capital	Mar 25, 2026	Maintains	Buy	$23.00 → $7.00	19%
Ascendiant Capital	Nov 20, 2025	Maintains	Buy	$22.00 → $23.00	19%

The case for and against

Updated Sep 13, 2026

Bull case

Aclarion is a healthcare technology company with a positive outlook as it gains traction in the market for its Nociscan product, which provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. With commercial agreements, increased marketing efforts, and an expanding share count, the company is investing in sales, R&D, and IR to drive future growth. While risks exist, such as slower enrollment in clinical trials, the company's strong cash position and potential market opportunity make it a promising investment with a 12-month price target of $7.50.

Bear case

Aclarion is facing challenges with its CLARITY trial, with initial data analysis and disclosure of early interim results delayed until Q4 2026. Additionally, while the company has a healthy cash runway, they also authorized a share-repurchase program, suggesting potential concerns about their current positioning and valuation. The delay in trial data and mixed signals about financial confidence could indicate underlying issues with the effectiveness and potential market success of Nociscan.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.